Results 31 to 40 of about 923 (130)

The efficacy of azvudine in treating hospitalized COVID-19 patients: a retrospective single-center cohort analysis. [PDF]

J Thorac Dis
Background Although coronavirus disease 2019 (COVID-19) is no longer classified as a Public Health Emergency of International Concern (PHEIC), the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to undergo genetic mutations ...
Lei H, Ye YW, Zhou YJ, Mao YF, Fang Y, Chen PP, You WW, Li S, Xu YY.   +8 more
europepmc   +3 more sources

Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study [PDF]

BMC Infectious Diseases
Background and aim Two oral antivirals (Nirmatrelvir- ritonavir and Azvudine) are widely used in China practice during the Omicron wave of the pandemic.
Xiaobo Han, Darui Gao, Chenglong Li, Xin Yuan, Junchang Cui, Weiguo Zhao, Fei Xie, Kaifei Wang, Yuhong Liu, Guoxin Muo, Na Xi, Mengli Zheng, Rentao Wang, Kun Xiao, Dahui Zhao, Xinxin Zhang, Xinjie Han, Bo Wang, Tiantian Zhang, Wuxiang Xie, Lixin Xie   +20 more
doaj   +3 more sources

Real-world efficacy of oral azvudine in hospitalized patients with COVID-19: A multicenter retrospective cohort study

Journal of Infection and Public Health
Background: Azvudine has become a widely used treatment for COVID-19 in China. Our study aimed to assess the real-world efficacy of azvudine in hospitalized COVID-19 patients during the omicron variant surge.
Rui Han, Youhong Guan, Pulin Li, Min Tang, Guanghe Fei, Daxiong Zeng, Ran Wang   +6 more
doaj   +3 more sources

Adherence and recommended optimal treatment to Azvudine application for the treatment of outpatient COVID-19 patients: A real-world retrospective study [PDF]

Heliyon
Background: Azvudine was approved for the treatment of coronavirus disease 2019 (COVID-19) in China and has been widely used since the outbreak in December 2022. However, real-world research on the adherence of Azvudine is lacking.
Hui Yang, Ying Zhang, Zhaojian Wang, Man Xu, Yushu Wang, Yi Zhang, Xin Feng, Zhuoling An   +7 more
doaj   +3 more sources

Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort studyResearch in context [PDF]

EClinicalMedicine, 2023
Summary: Background: As the COVID-19 pandemic continues to spread, the number of associated deaths continues to increase, especially among those with pre-existing conditions.
Yuming Sun, Liping Jin, Yating Dian, Minxue Shen, Furong Zeng, Xiang Chen, Guangtong Deng   +6 more
doaj   +4 more sources

Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study

Infection and Drug Resistance, 2023
Xiang Zhao,1 Yuan Cheng,1 Meng Zhang,1 Bianba Qianda,2 Baima Zhouma,3 Bianba Yangzhen,3 Yao Zheng,4 Shuo Zhang,5 Huiying Zhao6 1Department of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing, People’s Republic of China ...
Zhao X, Cheng Y, Zhang M, Qianda B, Zhouma B, Yangzhen B, Zheng Y, Zhang S, Zhao H   +8 more
doaj   +5 more sources

Azvudine potently inhibits African swine fever virus replication in vitro [PDF]

Virus Research
African swine fever (ASF), caused by the African swine fever virus (ASFV), is a highly contagious and often fatal disease affecting domestic pigs and wild boars, resulting in substantial economic losses globally.
Fei Xi, Bozhang Sun, Lei Duan, Biao Lu, Shujing Zhang, Hong Tian, Fan Yang, Zixiang Zhu, Haixue Zheng, Guoliang Zhu, Lijie Tang   +10 more
doaj   +3 more sources

A Retrospective Analysis of Azvudine in Patients with COVID-19 and Pre-existing Cancer. [PDF]

J Cancer
Objectives: Azvudine has been recommended as a potential treatment for the recently discovered Coronavirus disease (COVID-19) in 2019. However, the effectiveness of Azvudine in individuals who have both COVID-19 and pre-existing cancer remains uncertain.
Li F, Zheng K, Qi X, Cui K, Yang J, Hao Z.   +5 more
europepmc   +4 more sources

Association of eosinopenia with worsening prognosis in hospitalized Azvudine-treated COVID-19 patients: a retrospective cohort study [PDF]

Frontiers in Immunology, 2023
BackgroundCurrent guidelines prioritize the use of Azvudine in Coronavirus Disease 2019 (COVID-19) patients, while biomarkers for prognosis in Azvudine-treated COVID-19 patients are still lacking.
Xiaomin Wang, Xiaomin Wang, Xiaomin Wang, Xiaomin Wang, Xiaomin Wang, Xiaomin Wang, Xiaomin Wang, Yating Dian, Yating Dian, Yating Dian, Yating Dian, Yating Dian, Qian Zhou, Qian Zhou, Qian Zhou, Qian Zhou, Qian Zhou, Guangtong Deng, Guangtong Deng, Guangtong Deng, Guangtong Deng, Guangtong Deng, Rui Wei, Rui Wei, Furong Zeng, Furong Zeng   +25 more
doaj   +2 more sources

Systematic evaluation of therapeutic effectiveness of Azvudine in treating COVID-19 hospitalized patients: a retrospective cohort study [PDF]

Frontiers in Cellular and Infection Microbiology
BackgroundAzvudine, a repurposed oral small molecule antiviral drug, has potential effects in combating the SARS-CoV-2 virus. However, studies on its clinical efficacy in patients with COVID-19 are still limited and controversial, and further research ...
Yingkai Xu, Yingkai Xu, Yuan Huang, Zihan Yuan, Zihan Yuan, Wanbing Liu, Li Wang, Lei Liu   +7 more
doaj   +4 more sources